A total of 28 people, of 94 evaluated in Camagüey, have been included to be favored with the clinical trial of NeuralCIM (nasal drops) in patients with the phenotype of suffering from Alzheimer's, with the purpose of stopping the disease.
Cuba joins the international campaign for World Alzheimer's Day, which is celebrated every September 21 to raise awareness about dementia and challenge the stigma.